Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dimerix Limited ( (AU:DXB) ) has issued an announcement.
Dimerix Limited announced the issuance of 1,189,968 fully paid ordinary securities, which are set to be quoted on the Australian Securities Exchange (ASX) under the code DXB. This move, resulting from the exercise of options or conversion of other securities, is expected to enhance the company’s financial flexibility and potentially strengthen its market position.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative therapies for unmet medical needs. The company primarily engages in research and development of pharmaceutical products, aiming to address significant health challenges.
Average Trading Volume: 3,244,024
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$354.4M
Find detailed analytics on DXB stock on TipRanks’ Stock Analysis page.